Incorporating New Therapeutic Strategies in the Treatment of Hodgkin Lymphoma
  • CME

In this on-demand Webcast of a CCO symposium at ASH 2017, Ranjana Advani, MD, leads an expert panel with Robert W. Chen, MD; Andrew Evens, DO, MSc, FACP; and Pier Luigi Zinzani, MD, PhD, as they review and discuss the latest clinical strategies for managing patients with Hodgkin lymphoma.
Ranjana Advani, MD
Program Director
Robert W. Chen, MD
Andrew M. Evens, DO, MSc, FACP
Pier Luigi Zinzani, MD, PhD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: January 24, 2018 Expiration: January 23, 2019

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Assess the results of recent trials of response-adapted frontline therapy in Hodgkin lymphoma and how they will influence clinical practice
  • Choose optimal intensified frontline treatments for patients with advanced Hodgkin lymphoma, incorporating available and emerging treatment options
  • Describe the application and limitations of FDG-PET imaging in the early assessment of response to treatment in Hodgkin lymphoma
  • Plan therapeutic strategies to prevent second relapse after transplantation in patients with Hodgkin lymphoma at risk of progression
  • Evaluate the clinical data on available and promising investigational agents for patients with relapsed/refractory Hodgkin lymphoma
  • Determine optimal sequencing of brentuximab vedotin and immune checkpoint inhibitors in the treatment of patients with Hodgkin lymphoma

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Ranjana Advani, MD

Professor of Medicine
Department of Oncology
Stanford University Medical Center
Stanford Cancer Center
Stanford, California

Ranjana Advani, MD, has disclosed that she has received consulting fees from Bayer, Bristol-Myers Squibb, Cell Medica, Genentech/Roche, Gilead Sciences, Juno, NanoString, Pharmacyclics, Spectrum, and Sutro and funds for research support from Agensys, Bristol-Myers Squibb, Celgene, Forty Seven Inc, Genentech/Roche, Janssen, Infinity, Kura, Merck, Millennium, Pharmacyclics, Regeneron, and Seattle Genetics.


Robert W. Chen, MD

Associate Professor
Department of Hematology
City of Hope
Duarte, California

Robert W. Chen, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Genentech, Merck, and Seattle Genetics and funds for research support from Bristol-Myers Squibb, Pharmacyclics, and Seattle Genetics.

Andrew M. Evens, DO, MSc, FACP

Professor and Chief
Division of Hematology/Oncology
Tufts Medical Center
Boston, Massachusetts

Andrew M. Evens, DO, MSc, FACP, has disclosed that he has received consulting fees from AbbVie, Affimed, Amgen, Celgene, Kite Pharma, Merck, Millennium, Novartis, Pharmacyclics, Seattle Genetics, and Spectrum; fees for non-CME/CE services from Celgene; and funds for research support from Millennium/Takeda and Seattle Genetics.

Pier Luigi Zinzani, MD, PhD

Professor of Hematology
Chief of Lymphoma and CLL Unit
Institute of Hematology "Seràgnoli"
University of Bologna
Bologna, Italy

Pier Luigi Zinzani, MD, PhD, has disclosed that he has received consulting fees from Astellas, Bristol-Myers Squibb, Celgene, Gilead Sciences, Janssen, Lundbeck, Merck, Mundipharma, Nordic Nanovector, Roche, Sandoz, Servier, Takeda, and Verastem.


Megan Cartwright, PhD

Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with Hodgkin lymphoma.


The goal of this activity is to improve participants’ competence in and performance at selecting treatment for individual patients with Hodgkin lymphoma.

Physician Continuing Medical Education

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 24, 2018, through January 23, 2019:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

In this downloadable slideset, Elizabeth R. Plimack, MD, MS, discusses the current clinical rationale and most recent data on immune checkpoint inhibitors for patients with advanced bladder cancer. Click here to use our online tool to see how to select optimal therapy for your patients.

Released: April 30, 2018

In this archived Webcast, Raajit K. Rampal, MD, PhD, provides expert perspectives on the diagnosis and optimal management of patients with polycythemia vera or myelofibrosis.

person default Raajit K. Rampal, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 30, 2018 Expiration: April 29, 2019

Induction therapy in mantle cell lymphoma is rapidly evolving. How do you treat your patients with MCL?

Julie M. Vose, MD, MBA Released: April 30, 2018

Download this PDF resource of expert recommendations on the optimal use of immune checkpoint inhibitors in patients with advanced NSCLC, including therapy selection and adverse event management.

Released: April 30, 2018


Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

This activity is supported by educational grants from
Merck & Co., Inc.
Takeda Oncology
Seattle Genetics

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?